

FOR IMMEDIATE RELEASE:

Creatus Biosciences Inc. Appoints Chris Wagner to the Board of Directors

Vancouver, BC – September 27th, 2022 / Creatus Biosciences Inc. (“Creatus”), an industrial biotechnology company producing xylitol sweetener from abundant corn wastes, is pleased to welcome Chris Wagner as a member of the Board of Directors.

“Chris brings a very strong strategic background and the right kind of experience to advise on commercialization and partnership deals for Creatus” says Ken Hallat, Executive Chair of Creatus. “Creatus will greatly benefit from Chris as we continue our partnerships with key industry players seeking value from corn fibre waste to high-value xylitol”.

Xylitol demand is steadily increasing as a replacement for high-fructose corn syrup and sugar, fuelled by global obesity and children’s oral health pandemics. The unique properties of xylitol as an anti-microbial, anti-cavity, low-glycemic sweetener with 1-to-1 sweetness to sugar, make it an ideal substitute while reducing overall calories, improving oral health and matching bulking ability of sugar. Over 65% of xylitol is used in the chewing gum industry with the largest new growth opportunities in confectionary, pharmaceutical and personal care sectors. Currently, xylitol is produced chemically using a metal catalyst from pure xylose processed from trees or food crop.

Creatus has developed a fully-integrated biorefinery system for xylitol production from non-wood, non-food biomass sources. The process disrupts current chemical production of xylitol with an over 40% lower cost of production and 10x lower carbon output, using corn products and sugarcane wastes.

About Chris Wagner

Chris Wagner has over 25 years of experience in commercialization and product development in the life sciences industry. Mr. Wagner is currently Founder and CEO of ImmunoFlex focusing on immune system genomics and a board member of Filament Health a drug discovery and development company. Mr. Wagner was recently CEO and Director of Emerald Health Therapeutics, where he filed 17 patents, launched an international brand, and increased the market capitalization by 400%. Prior to Emerald, Mr. Wagner held several executive positions including Founder & CEO of Imagia-Canexia Health (currently selling its medical products globally), CEO of Sirius Genomics (sold to a strategic investor), Vice President of Business Development of Aspreva Pharmaceuticals (sold to a strategic investor), and Global Team Leader at Eli Lilly.

Mr. Wagner is an Accredited Director and received executive education at The Wharton School and a Bachelor of Science in Organic Chemistry from UBC.

About Creatus

Creatus Biosciences Inc. is a biotechnology company building industrially-scalable fermentation processes to produce high-value products from low-value industry and agriculture wastes. Creatus has four granted patents with additional in process.

For Creatus:

Dara Djafarian

President

dara@creatusbio.com